WHO to consider adding obesity drugs to 'essential' medicines list https://ift.tt/1H39sVd

The request to consider obesity drugs was submitted by three doctors and a researcher in the United States. It covers the active ingredient liraglutide in Novo Nordisk's obesity drug Saxenda, which will come off patent soon, allowing for cheaper generic versions. The panel could reject the request or wait for more evidence. A decision by the WHO to include Saxenda and eventual generics on the list would mark a new approach to global obesity by the health agency.

from Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/5Kq7ryP